Millicent Pharma has announced a multimillion-pound investment to increase automation and manufacturing capacity at its Larne facility in Northern Ireland, alongside plans to create more than 20 jobs. Capital spending has begun at the site, where the company makes women’s health therapies, but it has not published a detailed equipment list or a quantified production increase.
The recruitment programme is expected to take the local workforce from approximately 50 to about 70 people, with positions across technical operations, production supervision, engineering and quality assurance. Vacancies were being advertised in early October, while the wider capital programme will continue over several years. The timing of individual equipment installations and the number of positions attached to each part of the expansion have not been disclosed.
Established in 2018 with backing from its founders and Carlyle Group, Millicent develops and markets therapies covering contraception and hormone replacement treatment. It operates manufacturing facilities in Larne and Fajardo, Puerto Rico, with corporate offices in Dundalk and New Jersey. The investment concerns an existing plant with both commercial production and research functions, rather than construction of a new factory.
Millicent’s Larne site, on Old Belfast Road in Millbrook, has more than 50,000 sq ft of space supporting a research and development centre and manufacturing operations for rings and other precision hormonal dosage forms. The product range requires control over formulation, component handling and process parameters, together with batch records capable of demonstrating that each lot meets its specifications. The company has not said which of those activities will receive new automation first.
Additional automation in a pharmaceutical plant must be introduced within a tightly defined quality system. Faster material handling or more repeatable machine settings are valuable only if the process continues to meet approved specifications and any changes are supported by qualification and validation evidence. Documentation, cleaning procedures, traceability and staff training therefore remain part of the engineering workload when equipment is replaced or reconfigured.
The Medicines and Healthcare products Regulatory Agency lists Millicent Pharma (NI) Limited as the holder of a manufacturing authorisation for the Larne address. Its registered scope covers specified non-sterile products, including vaginal rings, batch certification, secondary packaging and chemical or physical quality control testing. A separate authorisation covers defined investigational medicinal product activities, establishing the site’s existing regulatory permissions rather than approval of the announced investment.
Planned automation changes will need to be assessed against each validated manufacturing process, the applicable equipment controls and supporting batch records. That work may include installation qualification, operating limits, alarm handling and evidence that product quality remains within specification. Millicent has yet to identify specific machines, production lines or additional throughput targets for the investment.
Where automated equipment is introduced into a validated manufacturing process, the organisation may need to demonstrate that critical parameters remain controlled over the intended range of operating conditions. Records can include equipment settings, process measurements, alarms and checks needed for the batch history. The precise approach depends on product risks and process requirements; Millicent has not attributed particular digital systems or data functions to the investment.
The additional engineering and quality roles are consistent with the work required to bring new equipment into regulated operation, although their individual assignments have not been specified. New capacity can increase the volume of sampling, inspection, batch review and maintenance even when some handling tasks become more automated. Production personnel must also be trained against controlled procedures before changed lines or equipment can be used routinely.
An MHRA inspection dated 23 September 2026 is recorded against the Larne site, and the regulator lists a good manufacturing practice compliance certificate for the authorised operation. That is evidence about the site’s inspected quality arrangements, not a regulatory sign-off for machinery which has yet to be installed or qualified. Future changes must remain within the applicable licence, quality system and product-specific requirements.
Research activity on the same site can assist the transfer of processes into routine production, since formulation characteristics, operating parameters and analytical methods must remain coherent between development work and commercial batches. Even then, laboratory success does not establish consistent factory output. Repeatability, acceptable variation and performance at the intended production scale must be demonstrated with the actual installed equipment.
Millicent participates in the Larne Community Wealth Building Partnership, a local initiative led by enterprise organisation LEDCOM, and its announcement associates the expansion with local recruitment and training. No separate numerical training pledge has been published, leaving the announced job additions as the most directly measurable workforce commitment. The recruitment mix suggests that the company expects a greater demand for production and technical oversight, rather than automation eliminating those functions.
Work on the facility and recruitment programme is under way, with the company seeking additional engineering and quality expertise as manufacturing changes are introduced. Millicent has not given a completion date or a post-investment production-volume target. The commissioning and validation of the new equipment will be the relevant measures of when the expansion enters routine regulated service.
